Hydrogen Research Study
← Back to Research Library
Preclinical animal evidenceAnimal studyhydrogen-rich water

Combating oxidative stress and inflammation in gentamicin-induced nephrotoxicity using hydrogen-rich water.

Mustafa Oguz Cumaoglu, Mustafa Makav, Serpil Dag, Ayfer Yildiz Uysal, Lale Baser, Tyler W LeBaron, Duried Alwazeer · Tissue & cell · 2024

Research-use notice

Independent study record

Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.

H2HUBB Research Library branded molecular hydrogen research image
Primary topic Kidney and Renal Health
Evidence type Preclinical animal evidence
Publication type Animal study
Hydrogen method hydrogen-rich water

H2HUBB TAKEAWAY

In rats, immunohistochemically, 8-OHdG, MDA, and Bax expressions increased in the gentamicin group compared to the control group, whereas they decreased in the gentamicin+hydrogen group compared to the gentamicin group. These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.

What the Findings Mean

H2HUBB reviewed how hydrogen-rich water affected the outcomes measured in rats. Immunohistochemically, 8-OHdG, MDA, and Bax expressions increased in the gentamicin group compared to the control group, whereas they decreased in the gentamicin+hydrogen group compared to the gentamicin group.

What the Researchers Studied

The researchers studied rats. The study used a preclinical animal experiment. The comparison condition was control condition or baseline measurements.

What Effects Did Molecular Hydrogen Have?

This study aims to examine the effects of hydrogen-rich water (HRW) on gentamicin-induced renal damage in rats. Thirty-two rats were equally divided into four groups, including control (no treatment), hydrogen, gentamicin, and gentamicin+hydrogen. Data showed that while MDA (control P<0.0001, H2P<0.0001, ‎Genta+H2P<0.0007), TNF-α (control P<0.0002, H2P<0.0040, ‎Genta+H2P<0.0381), IL-6 (control P<0.0044, H2P<0.0070, ‎Genta+H2P<0.0109), endocan (control P<0.0460, H2P<0.0286, ‎Genta+H2P<0.0452), and endoglin (control P<0.0131, H2P<0.0164, ‎Genta+H2P<0.0397), urea (control P<0.0024, H2P<0.0001, ‎Genta+H2P<0.0180), and creatinine parameters (control P<0.0017, H2P<0.0178, ‎Genta+H2P<0.0011) increased in the gentamicin group compared to the other groups, a decrease in these parameters was observed in the gentamicin+hydrogen group compared to the gentamicin group. Immunohistochemically, 8-OHdG, MDA, and Bax expressions increased in the gentamicin group compared to the control group, whereas they decreased in the gentamicin+hydrogen group compared to the gentamicin group. Hydrogen may be an alternative treatment for oxidative stress-induced nephrotoxicity.

Why These Findings Matter

These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.

How Strong Is This Evidence?

This is preclinical animal evidence from a preclinical animal experiment. It is most informative for the disease model, mechanisms, biomarkers, and outcomes directly measured in the study.

Technical Study Details

H2HUBB classifies this publication as animal study with preclinical animal evidence. The research population or model was rats. The study used a preclinical animal experiment. The hydrogen delivery method was hydrogen-rich water.

Limitations and Safety

No separate limitations or safety findings were identified in the current-study source text available to H2HUBB.

Original Study and H2HUBB Research Context

H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.